Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Depreciation & Amortization (CF): 2018-2024

Historic Depreciation & Amortization (CF) for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to $2.8 million.

  • Avidity Biosciences' Depreciation & Amortization (CF) rose 57.14% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 31.04%. This contributed to the annual value of $2.8 million for FY2024, which is 33.27% up from last year.
  • As of FY2024, Avidity Biosciences' Depreciation & Amortization (CF) stood at $2.8 million, which was up 33.27% from $2.1 million recorded in FY2023.
  • Avidity Biosciences' Depreciation & Amortization (CF)'s 5-year high stood at $2.8 million during FY2024, with a 5-year trough of $400,000 in FY2020.
  • For the 3-year period, Avidity Biosciences' Depreciation & Amortization (CF) averaged around $2.1 million, with its median value being $2.1 million (2023).
  • Data for Avidity Biosciences' Depreciation & Amortization (CF) shows a peak YoY soared of 119.09% (in 2022) over the last 5 years.
  • Avidity Biosciences' Depreciation & Amortization (CF) (Yearly) stood at $400,000 in 2020, then soared by 59.75% to $639,000 in 2021, then soared by 119.09% to $1.4 million in 2022, then skyrocketed by 50.07% to $2.1 million in 2023, then soared by 33.27% to $2.8 million in 2024.